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Abstract A broad region on chromosome 12p13 has been
intensely investigated for novel genetic variants associated
with Alzheimer disease (AD). We examined this region
with 23 microsatellite markers using 124 North European
(NE) families and 209 Caribbean Hispanic families with
late-onset AD (FAD). Significant evidence for linkage was
present in a 5-cM interval near 20 cM in both the NE FAD
(LOD=3.5) and the Caribbean Hispanic FAD (LOD=2.2)
datasets. We further investigated these families and an
independent NE case–control dataset using 14 single
nucleotide polymorphisms (SNPs). The initial screening of
the region at ∼20 cM in the NE case–control dataset
revealed significant association between AD and seven
SNPs in several genes, with the strongest result for
rs2532500 in TAPBPL (p=0.006). For rs3741916 in
GAPDH, the C allele, rather than the G allele as was
observed by Li et al. (Proc Natl Acad Sci U S A 101
(44):15688–15693, 2004), was the risk allele. When the
two family datasets were examined, none of the SNPs were
significant in NE families, but two SNPs were associated
with AD in Caribbean Hispanics: rs740850 in NCAPD2
(p=0.0097) and rs1060620 in GAPDH (p=0.042). In a
separate analysis combining the Caribbean Hispanic fami-
lies and NE cases and controls, rs740850 was significant
after correcting for multiple testing (empirical p=0.0048).
Subsequent haplotype analyses revealed that two haplotype
sets—haplotype C-A at SNPs 6–7 within NCAPD2 in
Caribbean Hispanics, and haplotypes containing C-A-T at
SNPs 8–10 within GAPDH in Caribbean Hispanic family
and NE case–control datasets—were associated with AD.
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Taken together, these SNPs may be in linkage disequilibrium
with a pathogenic variant(s) on or near NCAPD2 and
GAPDH.
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Introduction
Alzheimer disease (AD) occurs as a late-onset disorder with
increasing frequency after the age of 65. Genome-wide
linkage analyses have identified several loci as potential
sites containing late-onset AD susceptibility genes [1–3].
One of the most consistent results has been on chromosome
12p. Linkage was originally reported at ∼45 cM (LOD=
3.5) [3]. Previously, we confirmed this locus using 53 North
European families multiply affected by AD with the
strongest evidence for linkage near the markers D12S358
(26 cM) and D12S96 (68 cM) [4], and in 79 Caribbean
Hispanic families where two-point linkage analysis using
affected sib pairs yielded LOD scores of 3.15 at D12S1623
(16 cM) and 1.43 at D12S1042 (49 cM) [5]. Although
several genes on chromosome 12 have been implicated as
potential sites for AD-associated variants (http://www.
alzgene.org), none have been confirmed.
It is not surprising that several independent studies have
reported significant support for linkage in different but nearby
regions of chromosome 12p, given the complex underlying
biology of AD. It has been shown that the actual disease locus
can reside as far as 20 cM away from the markers with the
maximumLOD scores [6, 7]. For example, after fine mapping
and genotyping additional family members [3], Scott and
colleagues [8] found that support for linkage expanded to
include ∼40 cM over both arms of the chromosome between
26 cM (D12S358 LOD=2.5) and 67 cM (D12S390 LOD=
2.0). Thus, potentially the AD-linked locus includes the entire
67 cM interval on chromosome 12p.
In this study, we fine mapped the chromosome 12
locus using linkage analysis with 23 microsatellite
markers (14–83 cM) in two expanded groups of families
multiply affected by late-onset AD (FAD) consisting of
124 North European and 209 Caribbean Hispanic
pedigrees. In the regions with the highest support for
linkage, we analyzed 14 single nucleotide polymorphisms
(SNPs) that were chosen based on a report of significant
association between sporadic AD and variations in or




We used two FAD datasets: 124 North European families
and 209 Caribbean Hispanic families. The North European
FAD dataset included 685 family members, and the
Caribbean Hispanic FAD dataset included 1,147 family
members who were recruited in the Dominican Republic,
Puerto Rico, and in New York City. The clinical character-
istics of the North European FAD [4] and Caribbean
Hispanic FAD [10] datasets have been previously described
and have a mean age at onset of 70 (SD=9) and 73 (SD=
11) years, respectively. The third cohort consisted of 183
patients with AD (36% males) and 224 controls (41%
males) of North European ancestry (Britain, France,
Germany) drawn from the same populations as the North
European FAD dataset [11]. The mean age-at-onset for
cases was 76 years (SD=7), and the mean age at follow-up
for unrelated controls was 73 years (SD=8). The character-
istics of the three datasets are summarized in Table 1.
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The diagnosis of AD was based on direct examination,
guided by the National Institute of Neurological Disorders
and Stroke–Alzheimer’s Disease and Related Disorders
Association (NINCDS–ADRDA) diagnosis criteria [12].
Informed consent was obtained from all individuals par-
ticipating in the study.
Genotyping
Genomic DNA was isolated from blood samples using a
QIAGEN kit. Prior to performing linkage analysis, we
checked for Mendelian inconsistencies in marker data using
the PEDCHECK program [13]. In the North European and
Caribbean Hispanic FAD datasets, we genotyped 23 micro-
satellite markers mapped on chromosome 12 at an average
inter-marker distance of ∼3.1 cM (14–83 cM) according to
the Marshfield Map set 13 (http://research.marshfieldclinic.
org/genetics; Table 2). The PCR conditions for genotyping
of the microsatellite makers were obtained from the
Genome Database (www.gdb.org). For the SNP-based
study, we focused on the 167-kb interval at 20 cM of
chromosome 12p13, which was prioritized based on the
strongest support for linkage in our FAD datasets and the
report of significant association between sporadic AD and
variations nearby GAPDH [9]. From a public database
(www.ncbi.nlm.nih.gov/SNP/), we identified 14 SNPs in
the intragenic sequence of seven genes with minor allele
frequencies >8%. This selection shown in Table 3 included
five SNPs that were significant in an earlier study [9]. SNP
genotyping was performed using the GenomeLab
SNPstream System (Beckman Coulter Inc., Fullerton, CA,
USA) [14]. Primer sequences were designed using software
provided at www.autoprimer.com (Beckman Coulter Inc.,
Fullerton, CA, USA) and are available upon request. APOE
genotyping was performed as previously described [15]. A
subset of 100 samples was genotyped twice for every SNP
with a concordance rate of 99%.
Statistical analyses
Linkage analysis We conducted two-point linkage analy-
ses, considering both dominant and recessive modes of
inheritance under an affecteds-only model [16, 17]. For all
linkage analyses, we used microsatellite markers only, and
assumed a susceptibility allele frequency of 0.001, and
penetrance values of 0.001 for gene carriers and 0.0 for
non-carriers. Although these affecteds-only parameters are
artificial, they lead to statistical tests with properties that are
comparable to ‘model-free’ analyses when studying com-
mon diseases [18]. The analysis was implemented using the
MLINK program from the FASTLINK package [19, 20].
We then performed a multipoint affected sibpair linkage
analysis using GENEHUNTER (version 2.1) to increase the
information content at a given chromosomal location. For
this analysis, we combined the Hispanic and North
European FAD datasets. To take into account differences
in allele frequency between the ethnic groups, we treated
one marker as two tightly linked markers (i.e., θ=0.0001
between members of each marker pair), and assigned one to
each ethnic group. We then computed ethnic-specific allele
frequencies for each marker. We used the weighted ‘all
pairs’ option, and set the increment function to scan at
1.0 cM. The sibpair analysis calculated the probability of
sharing zero, one, or two alleles (z0, z1, or z2) identical by
descent (IBD) between sib pairs, because susceptibility will
have probabilities (z0, z1, and z2) that differ from the
expected Mendelian proportions [21, 22]. The LOD score
was computed under the assumption of dominance, but
restricting the parameters to Holmans’s Triangle Inequality:
2z0≤z1≤1/2 and z0+z1+z2=1 [23, 24].
Association analysis of the case–control data Prior to the
allelic and genotypic association analyses, we assessed the
SNP genotype data for deviation from Hardy–Weinberg
Table 1 Demographic and clinical characteristics of the participants in the three independent datasets
Characteristic Family dataset Case–control dataset
North European Caribbean Hispanic NE cases NE controls
Total number of AD families 124 209 N/A N/A
Total number of subjects 685 1,147 183 224
Number of patients with AD 321 589 N/A N/A
Number of at-risk relatives 342 499 N/A N/A
Number of nuclear sibships (Q2 siblings genotyped) 163 272 N/A N/A
Number of patients per family, mean (range) 2.6 (1–6) 2.85 (1–12) N/A N/A
Number of at-risk persons per family, mean (range) 2.8 (0–18) 2.41 (0–15) N/A N/A
Mean age at onset (years) 70±9 73±11 76±7 73±8
Autopsy confirmation (1 per family) 58 (50%) 5 (2.2%) 0 (0%) 0 (0%)
Neurogenetics (2008) 9:127–138 129
equilibrium in the controls from the case–control dataset
and in the founders from the FAD datasets using the
PEDSTAT program [25]. For all association analyses, only
the SNP markers were used. We compared the allelic and
genotypic association in the case–control dataset using the
conventional χ2 test or Fisher’s exact test when the
expected frequency of one or more cells was fewer than
five [26]. In addition, we adjusted for covariates APOE ɛ4,
sex, and age-at-onset in patients, and age at the last
examination in controls using a multivariate logistic
regression analysis. For this analysis, we dichotomized the
SNP genotype as either having at least one or no copy of
the minor allele. Similarly, an APOE ɛ4 carrier was defined
as an individual having one or more APOE ɛ4 alleles. The
association was considered significant if the nominal p
value was below 0.05 in two independent datasets.
Haplotype associations were assessed using HAPLO.
STATS which computes a haplotype-specific empirical p
value for each haplotype and a permutation-based global p
value for the haplotype set [27].
Association analysis of the family data Association in the
FAD datasets was evaluated using FBAT version 1.7.2 [28].
Because our previous studies showed significant linkage in
this region [4, 5], we computed the empirical variance
function in the FBAT program to test the null hypothesis of
no association in the presence of linkage. An additive
genetic model was assumed throughout the study. Haplo-
type analyses using a sliding window approach in which
overlapping sets of two to three contiguous SNPs were
conducted in the Northern European case–control dataset
and Caribbean Hispanic FAD dataset because a number of
SNPs in these two datasets showed nominally significant
association in the two-point analysis. We computed
empirical p values for haplotype-specific p values, and
permutation-based global p values to adjust for multiple
testing for a specific haplotype set. To minimize the risk of
false positive findings from haplotype analysis, we per-
formed a multi-marker analysis using SNPs that were
significant in haplotype analysis. This analysis allows a
test of the null hypothesis without the required assumption
of no recombination between the SNPs [29]. We then
conducted an APOE ɛ4-positive conditional analysis
because earlier linkage analyses of the Caribbean Hispanic
families [5] and Caucasian families [30] revealed possible
influence of APOE on this region. For this purpose, we
considered an individual with AD and at least one APOE ɛ4
allele affected. An individual was considered unknown
otherwise. Conversely, we conducted an APOE ɛ4-negative
conditional linkage analysis, in which an individual with
AD was considered affected in the absence of an APOE ɛ4
allele.
Analysis of combined family and case–control data We
combined the Caribbean Hispanic families and Caucasian
cases–controls which those two datasets had nominally
significant associations for rs2532500 and rs740850. For
this purpose, we performed the DFAM procedure of the
PLINK package [31]. This approach combines family data
with unrelated cases and controls. The family data were
analyzed using the transmission disequilibrium test using
sibships as in sibTDT [32], and the case–control data were
analyzed using a clustered-analysis of the Cochran–Man-
tel–Haesnzel test, which assesses allelic association condi-
tional on cluster based on affection status. We examined the
SNPs after combining all three datasets for the sake of
completeness.
Assessment of linkage disequilibrium Linkage disequilib-
rium (LD) structure was examined with the program
HAPLOVIEW version 3.32 [33] (Fig. 2). Haplotype blocks
were defined using a confidence interval algorithm [34].
The default settings were used in these analyses, which
create 95% confidence bounds on D′ to define SNP pairs in
Table 2 Results for the two-point linkage analysis under autosomal
dominant and recessive models (affecteds-only model) for the North
European (NE) and Caribbean Hispanic (CH) samples









Order Marker Name cMa Dom Rec Dom Rec
1 D12S356 14.23 0.23 0.71 0.57 0.71
2 D12S374 14.53 0.58 0.37 0.15 0.00
3 D12S1623 15.69 0.13 0.10 2.21 2.07
4 D12S397 17.72 0.53 0.63 0.45 0.01
5 D12S1695 19.68 3.46 2.92 0.00 0.00
6 D12S77 20.27 0.40 0.61 1.83 1.53
7 D12S89 23.41 0.00 0.01 0.89 0.67
8 D12S391 26.23 0.05 0.24 0.02 0.00
9 D12S358 26.33 0.04 0.14 0.44 0.11
10 D12S269 30.60 0.14 0.12 0.58 0.13
11 D12S373 36.06 0.00 0.00 0.00 0.00
12 D12S1042 48.70 0.08 0.47 0.95 1.09
13 D12S1090 56.38 0.00 0.00 0.00 0.00
14 D12S1701 62.54 0.63 1.32 0.00 0.00
15 D12S390 67.63 0.16 0.06 0.00 0.00
16 D12S96 68.16 1.70 1.58 0.00 0.00
17 D12S398 68.46 0.28 0.38 0.00 0.03
18 D12S1632 71.61 1.91 1.60 0.00 0.00
19 D12S90 72.61 0.00 0.00 0.00 0.00
20 D12S83 75.17 0.56 0.59 0.00 0.00
21 D12S375 80.52 0.04 0.00 0.00 0.03
22 D12S1722 82.12 0.03 0.07 0.00 0.00
23 D12S92 83.19 0.91 0.67 0.04 0.18
Markers with LOD>1 are in bold.
Dom Dominant, Rec recessive
a The position in cM is based on the Kosambi map.
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strong LD. Haplotypes and their frequencies were estimated
using an accelerated expectation–maximization (EM) algo-
rithm similar to the partition/ligation method implemented
in HAPLOVIEW [35].
Results
Linkage analysis The analysis of the 23 microsatellite
markers from the pericentromeric region of chromosome
12 generated a peak overall two-point LOD score of 3.46 at
19.7 cM in the North European FAD dataset (Table 2,
Fig. 1). In the Caribbean Hispanic FAD dataset, we
observed two markers flanking the locus observed in the
North European dataset, with LOD scores 2.21 at 15.7 cM
and 1.83 at 20.3 cM. The multipoint linkage analysis of the
combined datasets yielded a modest positive LOD score of
2.24 at 20.2 cM confirming the prior linkage support for
this 5 cM region between 15 and 20 cM (Supplementary
Fig. 1). Thus, the two datasets independently support
linkage to the chromosome 12p13 region. In addition, the
North European FAD dataset also gave weakly positive
scores for three markers in a 4-Mb interval near 71 cM
(LOD≤1.91, Table 2).
Association analysis For the 14 SNPs within the 6.4–
6.6 Mb region (167 kb interval at 20 cM), we observed
seven SNPs with nominal p<0.05 in five different
neighboring genes in at least one of the three datasets
(Table 3): the TAP binding protein-like (TAPBPL); non-
SMC condensin I complex, subunit D2 (NCAPD2, also






































































Fig. 1 a Results of the two-point linkage analysis (affecteds-only
model) in the North European and Caribbean Hispanic families using
23 microsatellite markers on chromosome 12. LOD scores for
autosomal dominant mode of inheritance are presented. b Genomic
context and the positions of the selected single nucleotide poly-
morphisms for the prioritized chromosome 12p13 region
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known as CNAP1); GAPDH; cadherin 4, type 1, R-cadherin
(CDH4); and G protein-coupled receptor 92 (GPR92). The
strongest association with AD was observed for the T allele
of a non-synonymous SNP, rs2532500, in the TAPBPL gene
(genotype association p=0.006) in the North European
case–control dataset. In the logistic regression analysis
(Supplementary Table 1), three of the seven SNPs remained
significant in the univariate model. However, these SNPs
were no longer significant in a multivariate model that
adjusted for age, sex, and APOE.
The same set of 14 SNPs were examined in the two FAD
datasets using a single-point, family-based association
analysis [28]. None of the SNPs were associated with
FAD in the North European families. However, in the
Caribbean Hispanic FAD dataset, there were two significant
SNPs, one in the NCAPD2 (SNP 7: rs740850, p=0.0097),
the other in GAPDH (SNP 10: rs1060620, p=0.0418). Both
associations remained significant in the APOE conditional
analysis in APOE ɛ4-positives (rs740850, p=0.015; and
rs1060620, p=0.049).
We then performed association analysis after combining
the two datasets that had positive allelic association, namely
Caribbean Hispanic families and Caucasian cases and
controls (Table 4). We found rs2532500 and rs740850 to
be significantly associated with AD. For rs2532500, the T
allele was significantly associated with AD after correcting
for multiple testing (empirical p=0.0259); while for
rs740850, the A allele was significantly associated with
AD (empirical p=0.0048). However, when all three data-
sets were used for sake of completeness, none of the SNPs
were found to be significant. Only rs3741916 (empirical p=
0.0622), adjacent to rs740850 (empirical p=0.1115),
approached experimentalwise significance.
Haplotype analysis was performed in the North Europe-
an case–control and Caribbean Hispanic FAD datasets to
follow-up the significant findings in the single-point
analysis (Table 5). Haplotype analysis was not performed
in the North European FAD dataset because none of the
SNPs showed significant association in the single-point
analysis. In the North European case–control dataset, the
haplotypes containing the A allele at rs740850 (SNP 7)
were positively associated with AD, whereas the haplotypes
containing the G allele at rs740850 (SNP 7) were
protective. Although haplotypes containing the C allele at
rs2072374 (SNP 6) or the G allele at rs3741916 (SNP 8)
were significantly associated with AD, the direction of the
haplotype association (i.e., whether a haplotype was
deleterious or protective against AD) was inconsistent. In
the Caribbean Hispanic FAD dataset, a similar pattern of
haplotype association was observed. Haplotypes including
rs740850 (SNP 7) were significant. Specifically, haplotype
C-A at SNP 6–7 and haplotype C-A-C at SNP 6–7–8 were
positively associated with AD (Z=1.96–2.12, both haplo-
type-specific empirical p and global p<0.05). On the other
hand, haplotypes T-C-G at SNP 5–6–7 (rs7311174,
rs2072374, and rs740850) showed a consistent protective
effect on AD in the two datasets (North European case–
control set, haplotype-specific p value=0.032; global p
value=0.080; Caribbean Hispanic set, haplotype-specific p
value=0.005; global p value=0.0074). The T-C-G haplo-
type frequencies for the North European case–control
dataset and Caribbean Hispanic dataset were comparable
(0.359 and 0.408, respectively).
In the GAPDH gene, haplotypes that included the T
allele at rs1060620 (SNP 10) were significantly associated
with AD in both the North European case–control and
Caribbean Hispanic family datasets. Haplotype C-A-T at
Table 4 Results of single point association analysis combining family and case–control data
Pointwise Studywise
SNP # SNP Observed Expected Chi-square p Empirical p Empirical p
1 rs2532501 171 155.2 6.739 0.009434 0.0109 0.0649
2 rs2532500 177 159.2 8.54 0.00347 0.0064 0.0259
3 rs2008134 103 106.2 0.3203 0.5714 0.6123 0.9954
4 rs2072373 57 64.78 2.711 0.09968 0.1093 0.4803
5 rs7311174 99 98.95 8.68E−05 0.9926 0.9800 1.0000
6 rs2072374 98 98.35 0.003902 0.9502 0.9620 1.0000
7 rs740850 187 165.3 11.84 0.00058 0.0004 0.0048
8 rs3741916 76 87.93 5.293 0.02141 0.0177 0.1361
9 rs3741918 62 70.32 3.028 0.08183 0.0758 0.4076
10 rs1060620 92 95.93 0.5488 0.4588 0.4650 0.9810
11 rs1060619 89 92.26 0.3965 0.5289 0.5396 0.9937
12 rs740852 30 28.44 0.2185 0.6402 0.6549 0.9988
For estimation of empirical p value, we estimated empirical p value based on 10,000 replicates.
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North European case-control dataset
C T 0.365 -1.89 0.04500 0.08600
T C G 0.359 -2.24 0.03200 0.08000
C G 0.362 -2.33 0.02600 0.08900
G G 0.175 -2.54 0.01257 0.01547
C G G 0.174 -2.25 0.02100 0.17800
G A 0.049 -2.50 0.01300 0.02500
C A 0.794 2.63 0.01000 0.02500
G G A 0.049 -2.47 0.01412 0.00753
A G 0.006 1.73 0.03578 0.01547
A G T 0.006 1.87 0.01365 0.00753
G A T 0.050 -2.55 0.01300 0.03700
C A T 0.762 2.00 0.04600 0.03700
G C 0.291 -2.25 0.02800 0.07700
G A 0.634 1.97 0.05000 0.07700
C C 0.013 -2.43 0.00386 0.00617
A T 0.707 2.48 0.01620 0.00617
G C C 0.013 -2.43 0.00500 0.02200
G A T 0.632 2.12 0.03400 0.02200
Caribbean Hispanic family dataset
C T 0.397 -2.46 0.01395 0.05340
C C T 0.396 -2.29 0.02216 0.05880
C T C 0.249 -2.16 0.03063 0.16380
C A 0.409 1.96 0.04953 0.01320
C G 0.400 -2.72 0.00650 0.01320
T C A 0.419 1.96 0.04985 0.00740
T C G 0.408 -2.80 0.00504 0.00740
A C 0.377 2.06 0.03985 0.01100
G G 0.157 -2.37 0.01787 0.01100
C A C 0.377 2.12 0.03406 0.02860
A C A 0.355 2.19 0.02845 0.02060
A T 0.728 2.08 0.03719 0.09100
T C 0.146 -2.06 0.03948 0.09100
C A T 0.698 2.37 0.01656 0.09340
G T C 0.110 -2.33 0.01968 0.09340
T A 0.731 2.16 0.03094 0.02180
C A 0.022 -1.98 0.04781 0.02180
T C A 0.015 -1.97 0.04898 0.17501
C A G 0.022 -1.96 0.04722 0.06060
G C 0.468 2.07 0.03841 0.18920
c
Haplotypes in bold were positively associated with AD.
In the Caribbean Hispanic dataset, SNP 14 was not informative.
a Haplotypes with nominal p≤0.05 are shown.
b Global p values are based on permutation.
c rs740850 (shaded cells) was significantly associated with AD in the single point analysis after correcting for multiple testing.
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SNP 8–9–10 was significantly associated with AD in both
datasets (haplotype-specific empirical p=0.046, 0.017,
respectively), and haplotype T-A at SNP 10–11 (haplo-
type-specific empirical p value=0.03) was significantly
associated with AD in the Caribbean Hispanic family
dataset.
Lastly, the multi-marker analysis of Caribbean Hispanic
families supported the associations observed in the above
haplotype analysis for SNPs 7–8 (p=0.030), SNPs 9–10
(p=0.048), and SNPs 6–7–8 (p=0.015).
Discussion
We conducted multi-stage fine mapping of the chromosome
12 locus between 12p13.2 and 12q24.2, spanning 70 cM,
using two ethnically diverse FAD datasets and one case–
control AD dataset. We examined these two datasets
together because we hypothesized that there may present a
common susceptibility gene(s) for LOAD in this region,
since multiple datasets from more than one ethnic back-
ground yielded strong support for linkage and some of
Fig. 2 The linkage disequilibri-
um (LD) pattern in the North
European samples (a) and Ca-
ribbean Hispanic samples (b).
LD was estimated across several
single nucleotide polymor-
phisms in this chromosome re-
gion using the HAPLOVIEW
software. The five-color scheme
(white to red) represents the
increasing strength of LD. Boxes
with a D′ of 1 are shaded in
bright red. Cells with D′<1 are
shades of pink or red. Blue
represents D′=1, but with a low
confidence estimate for D′
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those studies reported significant allelic association. The
present linkage analyses of the NE Caucasian dataset as
well as the Caribbean Hispanic FAD dataset continue to
provide strong evidence for linkage at 15–20 cM on 12p.
The subsequent association study of 14 SNPs spanning a
167-kb region under the linkage peak (Fig. 1) revealed
nominally significant results for seven SNPs in a case–
control study. However, only two of these SNPs located in
two adjacent genes (NCAPD2 and GAPDH) demonstrated
nominally significant association with AD in one of two
FAD datasets (Table 3). Those two SNPs (rs2532500 and
rs740850) were significantly associated with AD, when we
combined the Caribbean Hispanic family data with the NE
Caucasian case–control data. Moreover, two haplotype sets
spanning SNPs 6–10 were significant; particularly, haplo-
type C-A at SNPs 8–9 located in NCAPD2 were signifi-
cantly associated with AD in both Caribbean Hispanic
families and in North European case–control dataset.
Our findings localize to the same region that was
identified by earlier reports, which detected a significant
association between AD and six SNPs in or nearby GAPDH
[9, 36]. Li and colleagues [9] observed somewhat different
allelic associations with AD in three case–control series and
one case–control series derived from a linkage study. This
series-to-series heterogeneity of disease risk suggests that
the observed AD associated SNPs are in fact in linkage
disequilibrium with a disease-causing allele at a nearby site.
All five SNPs that were significant in the study by Li and
colleagues [9] were included in our study; however, only
rs3741916 (SNP 8) generated a significant result. In our
North European case–control dataset, we found the C allele
of rs3741916 to be marginally associated with AD (p=
0.027). Further, in the Caribbean Hispanic FAD and NE
Caucasian case–control datasets, the haplotypes that include
the C allele at rs3741916 (e.g., haplotype C-A-T at SNPs 8–
10) were associated with AD (Table 5). This finding is
consistent with the results of a recent report by Lin and
colleagues [36], which conducted a study of North
American FAD and an AD case–control datasets using
eight SNPs in the PKP2P1, NCAPD2, and GAPDH genes.
Of those, seven of these SNPs were included in the current
investigation (Table 3). Lin and colleagues [36] found no
associations in the family-based study. However, they did
observe the CC genotype at rs3741916 (p=0.021) to be
marginally associated with sporadic AD, and the G allele at
rs3741916 be protective (p=0.014). In contrast, Li and
colleagues [9] observed the G allele at rs3741916 to be
over-represented in AD cases when compared with the
frequency the G allele in controls.
It has been suggested that the rs3741916 polymorphism
may affect the transcription of GAPDH since it is located at
−8 bp of the start codon [9]. The contradictory findings
across studies at rs3741916 may be due to allelic
heterogeneity, and argues against the functional signifi-
cance of this SNP. Another possible explanation for the
inconsistencies in allelic association was suggested by Lin
and colleagues [37], in which effects from multiple loci and
a varying degree of correlations among these variants can
lead to changing direction of association in different
samples. In our current datasets (Table 5), however, two
haplotype sets were consistently associated with AD: (1)
haplotype C-A at SNPs 6–7 was over-represented in AD in
Caribbean Hispanics; and (2) haplotypes containing C-A-T
at SNPs 8–10 were over-represented in both datasets.
Although our findings from two datasets are consistent to
some extent, further examination is necessary to probe the
region surrounding SNPs 6–10.
A recent report by De Ferrari and colleagues [38] proposed
the low density lipoprotein receptor-related protein 6 (LRP6),
located at ∼26 cM, as a susceptibility gene for late-onset AD,
and hypothesized that LRP6 alters function of Wnt signaling
components in AD. In our case–control dataset, we
examined two SNPs identified by the authors (rs1012672
in exon 18 and rs2302685 in exon 14), but neither were
significantly associated with AD (data not shown).
The current results support the hypothesis that the region
surrounding NCAPD2 and GAPDH at chromosome 12p13
may harbor an AD susceptibility gene(s), and the two
potential risk haplotypes are haplotype C-A at SNP 6–7
within NCAPD2 and haplotype C-A-T at SNPs 8–10 within
GAPDH. However, the LD for the GAPDH region extends
for approximately 130 kb (Fig. 2), and has a dense genomic
context, containing at least nine genes (Fig. 1). Given
significant results with several SNPs from the current study
as well as that of two published reports [9, 36], future
studies need to investigate a more dense and broad SNP
coverage of the interval on 12p detected by current linkage
studies.
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